Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | NOS3 | P29474 | 3/20 | 0.52 |
| ▸ | NOS1 | P29475 | 3/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9448919 | 0.81 | SLC6A4 (0.60) | HTR2CHTR2AHTR2BNOS3NOS1 | |
| SCHEMBL9448970 | 0.81 | NOS3 (0.52) | HTR2AKDM4EATMNOS3NOS1 | |
| SCHEMBL5013256 | 0.81 | HTR1D (0.56) | HTR2CHTR2AHTR2BNOS3NOS1 | |
| SCHEMBL9449013 | 0.81 | NOS3 (0.53) | NOS3NOS1CYP3A4CYP2C19NOS2 | |
| SCHEMBL3546179 | 0.81 | CYP3A4 (0.56) | HTR2CHTR2AHTR2BNOS3NOS1 | |
| SCHEMBL9448897 | 0.81 | NOS3 (0.54) | HTR2CKDM4EATMNOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5014962 | 0.80 | HTR1D (0.55) | HTR2CHTR2AHTR2BNOS3NOS1 | |
| Hydrochloric Acid SCHEMBL9449059 | 0.80 | CYP3A4 (0.55) | HTR2CHTR2AHTR2BNOS3NOS1 | |
| SCHEMBL9449028 | 0.78 | NOS3 (0.52) | HTR2AKDM4EATMNOS3NOS1 | |
| SCHEMBL9448835 | 0.78 | NOS3 (0.55) | NOS3NOS1CHRNA7CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0450345-B1 | Indole derivatives | MERCK PATENT GMBH (DE) | 1995-05-24 | — | — | EP | claimed |
| US-5227386-A | INDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-07-13 | — | — | US | claimed |
| JP-4235184-A | — | — | None | — | — | JP | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-7087750-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2006-08-08 | — | — | US | disclosed |
| EP-1513839-B1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE | NEUROSEARCH AS (DK) | 2006-07-26 | — | — | EP | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1326830-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
| WO-2002032863-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2002-04-25 | — | — | WO | disclosed |
| US-5599937-A | Heteroaromatic quinuclidinenes, their use and preparation | PHARMACIA AB (SE) | 1997-02-04 | — | — | US | disclosed |
| EP-0640082-A1 | HETEROAROMATIC QUINUCLIDINENES, THEIR USE AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023395-A1 | HETEROAROMATIC QUINUCLIDINENES, THEIR USE AND PREPARATION | KABI PHARMACIA AB (SE) | 1993-11-25 | — | — | WO | disclosed |
| US-5227386-A | INDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-07-13 | — | — | US | disclosed |
| US-5227386-A | INDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-07-13 | — | — | US | disclosed |
| JP-H04235184-A | INDOLE DERIVATIVE | MERCK PATENT GMBH | 1992-08-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | HTR2C 6/4885HTR2A 11/4885HTR2B 19/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | HTR2C 8/4885HTR2A 12/4885HTR2B 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.